<bill session="118" type="h" number="3093" updated="2024-07-24T15:22:19Z">
  <state datetime="2023-05-05">REFERRED</state>
  <status>
    <introduced datetime="2023-05-05"/>
  </status>
  <introduced datetime="2023-05-05"/>
  <titles>
    <title type="display">Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2023</title>
    <title type="short" as="introduced">Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2023</title>
    <title type="official" as="introduced">To require persons who undertake federally funded research and development of a biomedical product or service to enter into reasonable pricing agreements with the Secretary of Health and Human Services, and for other purposes.</title>
  </titles>
  <sponsor bioguide_id="H001094"/>
  <cosponsors>
    <cosponsor bioguide_id="C001131" joined="2023-05-26"/>
    <cosponsor bioguide_id="C001068" joined="2023-05-05"/>
    <cosponsor bioguide_id="D000216" joined="2023-05-05"/>
    <cosponsor bioguide_id="D000399" joined="2023-05-05"/>
    <cosponsor bioguide_id="G000586" joined="2023-05-05"/>
    <cosponsor bioguide_id="G000551" joined="2023-05-05"/>
    <cosponsor bioguide_id="J000298" joined="2023-05-05"/>
    <cosponsor bioguide_id="K000009" joined="2023-05-05"/>
    <cosponsor bioguide_id="K000389" joined="2023-05-05"/>
    <cosponsor bioguide_id="M001223" joined="2023-06-13"/>
    <cosponsor bioguide_id="N000147" joined="2023-05-05"/>
    <cosponsor bioguide_id="P000597" joined="2023-05-05"/>
    <cosponsor bioguide_id="P000607" joined="2023-05-05"/>
    <cosponsor bioguide_id="S001145" joined="2023-05-05"/>
    <cosponsor bioguide_id="S001218" joined="2023-05-05"/>
    <cosponsor bioguide_id="T000472" joined="2023-06-07"/>
    <cosponsor bioguide_id="T000481" joined="2023-08-04"/>
    <cosponsor bioguide_id="T000487" joined="2023-05-05"/>
  </cosponsors>
  <actions>
    <action datetime="2023-05-05">
      <text>Introduced in House</text>
    </action>
    <action datetime="2023-05-05" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2023-05-12">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Referral"/>
    <committee code="HSIF14" name="House Energy and Commerce" subcommittee="Health" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Government information and archives"/>
    <term name="Health care costs and insurance"/>
    <term name="Prescription drugs"/>
  </subjects>
  <amendments/>
  <summary date="2024-01-12T15:16:00Z" status="Introduced in House">Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2023

This bill requires companies that receive federal funding for research (or a license of the rights to a patent or regulatory test data) for a biomedical product or service to agree to set reasonable prices for the resulting biomedical product or service.

The Department of Health and Human Services (HHS) must determine a reasonable price based on a formula that ensures the U.S. price for the product or service is not more than the median price for the product or service in Canada and six other reference countries with, based on specified criteria, large economies and high incomes.

Companies entering these agreements also must report to HHS certain financial information related to the biomedical product or service involved.</summary>
</bill>
